UBS analyst Ashwani Verma lowered the firm’s price target on Viatris to $11 from $12 and keeps a Neutral rating on the shares. UBS is optimistic on the stock going into the quarter, and feels the valuation displacement since Q2 can correct when the company clarifies the lack of exposure with the upcoming Q3 report, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VTRS:
- Mylan challenge of two GLP-1 patents denied, Bloomberg says
- Early notable gainers among liquid option names on October 2nd
- Viatris agrees to divest Women’s Healthcare unit, API unit in India
- Viatris receives offer for divestiture of substantially all of OTC business
- Viatris announces agreements on remaining planned divestitures